Printer Friendly
The Free Library
14,679,167 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Axonyx Announces Compliance with NASDAQ SmallCap Market Minimum Bid Price Requirement.


Business Editors/Health/Medical Writers

NEW YORK New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
, N.Y.--(BUSINESS WIRE)--April 22, 2003

AXONYX INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:AXYX) today announced that it has received notification from NASDAQ that it has regained compliance with the minimum $1 bid price maintenance requirement for continued listing on the NASDAQ SmallCap Market under Marketplace Rule 4450(a)(5).

"Regaining compliance is evidence of increased investor confidence in Axonyx as we move forward into the Phase IIB IIB Institute for Independent Business
IIB Institute of International Business
IIB Institute of International Bankers
IIB International Investment Bank
IIB Indian Institute of Banking & Finance
IIB Included in Bankruptcy
IIB Ice, Ice, Baby
 and Phase III clinical trials on our lead drug compound Phenserine," stated Marvin S. Hausman, M.D., President and Chief Executive Officer of Axonyx.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , human memory disorders and prion-based illnesses such as Mad Cow Disease mad cow disease: see prion.
mad cow disease
 or bovine spongiform encephalopathy (BSE)

Fatal neurodegenerative disease of cattle. Symptoms include behavioral changes (e.g.
.

This press release may contain forward-looking statements or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the Securities and Exchange Commission, specifically Axonyx's Annual Report on Form 10-K. Axonyx cannot assure that it will maintain compliance with the minimum $1 bid price maintenance requirement. Axonyx has not announced the initiation of its planned Phase IIB and Phase III clinical trials for Phenserine and cannot make any assurances concerning the timing of the initiation of the Phase IIB and Phase III clinical trials. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 22, 2003
Words:290
Previous Article:Ohio Savings Bank Chooses Fiserv CBS Worldwide as Technology Partner; Scalability and Platform Deciding Factors for $14 Billion Organization.
Next Article:Avistar Statistics Show High Usage of Video Collaboration Technologies Among Financial Services Customers.
Topics:



Related Articles
Procept Announces Meeting Nasdaq SmallCap Listing Requirements; Ticker Symbol Returns to "PRCT".
Cyanotech Receives Delisting Warning Letter from Nasdaq.
Cell Pathways Receives Notice From Nasdaq.
AXONYX Announces Receipt of Delisting Letter from Nasdaq, Company Has Appealed.
Cell Pathways, Inc. Appeals Delisting Notification from Nasdaq.
Tripath Technology Granted Extension on Nasdaq SmallCap Market.
Axonyx Announces Transfer to the Nasdaq Smallcap Market.
Axonyx Receives Notice Related to Nasdaq Minimum Bid Price Rule.
Axonyx Regains Compliance with Nasdaq Minimum Bid Price Rule.
Axonyx Receives Notice Related to Nasdaq Minimum Bid Price Rule.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles